Ganitumab Provides No Benefit in Metastatic Ewing Sarcoma
Adding ganitumab to standard chemotherapy does not provide a benefit for patients with metastatic Ewing sarcoma, a phase 3 trial suggests.
Adding ganitumab to standard chemotherapy does not provide a benefit for patients with metastatic Ewing sarcoma, a phase 3 trial suggests.
Compared with the general population, survivors of childhood and adolescent cancers have an increased risk of 6 major psychiatric disorders.
The incidence of invasive breast cancer among childhood cancer survivors decreased from the 1970s to the 1990s.
Phase 3 data do not support adding ifosfamide to adjuvant methotrexate, doxorubicin, and cisplatin in patients with high-grade osteosarcoma.
Dinutuximab plus GM-CSF produced a low disease control rate that did not meet a historical benchmark.
There was no significant difference in overall survival between patients who received actinomycin-D and those who received carboplatin.
Survival outcomes for patients on the EURAMOS-1 trial were not affected by race/ethnicity or poverty exposure.
Ifosfamide improved event-free and overall survival.
Twenty-three percent of adolescents and young adults with sarcoma who used opioids during treatment had new persistent opioid use after treatment.
Lurbinectedin produced an overall response rate of 14.3% and a disease control rate of 57.1%.